Sunesis Pharmaceuticals, Inc.
(NASDAQ : SNSS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -1.14%129.730.0%$1301.61m
OCGNOcugen, Inc. -16.94%8.690.0%$1041.81m
NVAXNovavax, Inc. -13.19%159.4092.9%$626.12m
AMGNAmgen, Inc. -0.61%222.581.3%$545.63m
VRTXVertex Pharmaceuticals, Inc. -0.28%207.851.9%$517.40m
REGNRegeneron Pharmaceuticals, Inc. -0.54%444.322.7%$500.47m
GILDGilead Sciences, Inc. 1.48%63.681.0%$487.18m
ILMNIllumina, Inc. -4.00%399.753.5%$457.42m
ALXNAlexion Pharmaceuticals, Inc. -0.28%147.782.0%$340.58m
BIIBBiogen, Inc. -1.10%263.681.7%$316.91m
CRSPCRISPR Therapeutics AG -5.82%112.150.6%$266.47m
BNGOBionano Genomics, Inc. -19.71%6.870.0%$242.96m
EXASEXACT Sciences Corp. -5.96%119.0318.4%$221.98m
SGENSeagen Inc. -1.99%144.995.8%$204.86m
PACBPacific Biosciences of California, Inc. -8.57%28.317.2%$149.78m

Company Profile

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.